Related Experiment Video

Updated: Nov 20, 2025

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.6K

HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy

Per Anderson1,2, Natalia Aptsiauri1,3, Francisco Ruiz-Cabello1,2,3

  • 1Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.

Cellular & Molecular Immunology
|January 21, 2021
PubMed

Insights

Human leukocyte antigen class I (HLA-I) loss is a key mechanism of immune escape in colorectal cancer (CRC). Understanding HLA-I expression in CRC subtypes and metastases is crucial for improving T cell therapies.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • T cell-mediated immunotherapies show promise for colorectal cancer (CRC) but have limited response rates.
  • Colorectal cancer (CRC) is a heterogeneous disease with various classification systems.
  • Human leukocyte antigen class I (HLA-I) is crucial for antigen presentation to T cells and is often lost in cancers, facilitating immune escape.

Purpose of the Study:

  • To review the prevalence and mechanisms of HLA-I loss in CRC.
  • To examine HLA-I expression in relation to CRC molecular subtypes and metastatic dissemination.
  • To explore strategies for overcoming HLA-I loss and review the role of HLA class II (HLA-II) in CRC prognosis.

Main Methods:

  • Literature review summarizing existing research on HLA-I in CRC.
  • Analysis of HLA-I expression patterns in different CRC subtypes and metastatic contexts.
  • Discussion of therapeutic strategies targeting HLA-I loss.

Main Results:

  • HLA-I loss is a frequent event in CRC, contributing to tumor immune escape.
  • HLA-I expression varies across CRC molecular subtypes and metastatic sites.
  • Potential strategies exist to restore or bypass HLA-I loss for enhanced immunotherapy.

Conclusions:

  • Understanding HLA-I dynamics in CRC is essential for optimizing immunotherapy efficacy.
  • HLA-I loss represents a significant challenge in CRC treatment.
  • Further research into HLA-I and HLA-II is needed to improve patient outcomes in CRC.
Keywords:
Colorectal cancerHLA Class IImmune escape

More Related Videos

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

19.9K
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

15.1K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
866
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K